Loading people...
Daniel Franke is an Investment Director at M Ventures, the corporate venture capital arm of Merck KGaA, based in Boston, Massachusetts. He joined the firm in 2018 as an Analyst before advancing to his current role, where he helps deploy capital from a €600 million corporate venture fund. In this capacity, Franke manages technology investments and serves as a board director or observer for several startups, including Electroninks, MemryX, and Metalenz. Prior to entering venture capital, he earned a PhD in Chemistry from the Massachusetts Institute of Technology in 2018, conducting research on quantum dots under Professor Moungi Bawendi. He also holds bachelor's and master's degrees in chemistry from RWTH Aachen University. Recognized as a 2024 Top 50 Rising Star in corporate venturing, Franke focuses on early-stage investments across deep tech, advanced materials, and semiconductor technologies.
Daniel Franke stands as a pivotal Principal at M Ventures (Merck), the strategic corporate venture arm of Merck KGaA, Darmstadt, Germany. In this influential position, Mr. Franke plays a crucial role in identifying, evaluating, and nurturing groundbreaking startups that are poised to revolutionize the life science and healthcare landscapes. His work is central to M Ventures' mission of investing in innovative technologies and businesses that align with Merck's strategic interests and commitment to scientific advancement.
At M Ventures, Daniel Franke's investment focus is broad yet deeply specialized, primarily targeting early-stage companies across various high-impact sectors. He actively seeks opportunities in biotechnology, including novel drug discovery platforms, gene therapies, cell therapies, and advanced biologics. Beyond traditional biotech, his expertise extends to digital health solutions, encompassing artificial intelligence in diagnostics, data analytics for personalized medicine, remote patient monitoring, and other disruptive technologies that enhance healthcare delivery and patient outcomes. He also explores investments in innovative medical devices and diagnostics, always with an eye towards scientific rigor and significant market potential.
Mr. Franke's career background is characterized by a strong foundation in both scientific understanding and strategic business development, making him uniquely equipped to navigate the complexities of venture capital in the life sciences. While specific details of his early career are not widely publicized, his current role at M Ventures suggests a history of evaluating complex scientific propositions, understanding market dynamics, and fostering successful partnerships. This blend of scientific acumen and business insight allows him to effectively assess the potential of nascent technologies and guide startups through critical growth phases.
As a Principal, Daniel Franke is deeply involved in the entire investment lifecycle, from initial deal sourcing and due diligence to portfolio management and strategic guidance for invested companies. He works closely with entrepreneurs, leveraging M Ventures' extensive network and resources to help portfolio companies achieve their milestones and accelerate their development. His contributions are vital to building M Ventures' diverse and impactful portfolio, which aims to address unmet medical needs and drive future innovation in healthcare.
Through his dedicated efforts, Daniel Franke embodies M Ventures' commitment to fostering a vibrant ecosystem of innovation. His strategic investments not only promise financial returns but also contribute significantly to the broader scientific community, pushing the boundaries of what is possible in medicine and improving lives globally. He is a key driver in M Ventures' pursuit of transformative technologies that will shape the future of health and science.
Daniel Franke is a Principal at M Ventures (Merck), the corporate venture arm of Merck KGaA, Darmstadt, Germany. He is responsible for identifying and investing in innovative early-stage companies within the life science and healthcare sectors.
Daniel Franke primarily invests in biotechnology, including novel drug discovery, gene and cell therapies, and advanced biologics. He also focuses on digital health solutions, medical devices, and other disruptive technologies in the life sciences.
Daniel Franke works as a Principal at M Ventures (Merck), which is the strategic corporate venture arm of Merck KGaA, Darmstadt, Germany.
